Close menu




January 21st, 2021 | 12:14 CET

Varta, wallstreet:online, TeamViewer: These trends are sustainable

  • Investments
Photo credits: pixabay.com

Trends come and go. When everyone suddenly had to switch to their home office in March of last year, TeamViewer's stock was considered an absolute future stock. But times have changed. Home offices have become the new normal and are no longer sweeping anyone off their feet. Instead, the hot topics are electromobility and stock market trading. We present exciting stocks with a sustainable perspective.

time to read: 2 minutes | Author: Nico Popp
ISIN: DE000A2GS609 , DE000A0TGJ55 , DE000A2YN900

Table of contents:


    Varta: Electromobility "Made in Germany"?

    The list of hot stocks always includes one name: Varta. The German manufacturer supplies batteries primarily for hearing aids or headphones. Since the consumer electronics sector is booming, Varta is also benefiting strongly from the trend. A look at the customer list helps to classify the battery manufacturer's situation: In addition to Apple, Varta also supplies Samsung and Sony. Since demand is booming, Varta even wants to expand its capacities in 2021. The fact that Varta batteries will continue to sell in the future is almost certainly due to their technological superiority over cheap Asian competitors. Varta is continuously working on increasing its batteries' energy density to ensure that users can enjoy their devices for even longer.

    In addition to the traditional battery business, Varta also wants to enter battery production for electromobility. Public funding of EUR 300 million is to flow into this. Although competitors from Asia are well-positioned in this area, the fantasy surrounding battery production for electric cars drives Varta's share price. Some market observers see the share moderately valued up to a level of EUR 200. The share is currently trading at EUR 125, still some way from its all-time high of EUR 133.50. Given the growth potential, Varta could be promising in the long term.

    wallstreet:online: Trading boom drives the share

    wallstreet:online is also considered promising. The portal operator has been among the brokers for more than a year and offers a good range of services with its Smartbroker, which brought 70,000 new securities accounts in the first year. In total, Smartbroker has assets of more than EUR 2 billion. wallstreet:online was able to drive this growth cost-effectively thanks to its platforms and websites with "on-board" resources. In the forums of wallstreet-online.de and Finanznachrichten.de, the Company refers the relevant target group to its own broker offering. The media business units and the Smartbroker, therefore, complement each other perfectly.

    The Company's forecasts indicate that this growth could further continue in 2021, with a potential customer base reaching 120,000 by the end of 2021. The Company's portals are to provide even better support in the future. At wallstreet:online, one can imagine that customers will also trade actively from articles in the future. Since the portfolio's websites are an essential source of information for many private investors, this fits. Within a year, the number of page impressions rose from 200 to 300 million. Most private investors themselves probably know the fact that shares and self-determined investments are in vogue. Anyone who has shares from wallstreet:online in their portfolio and leaves them there can profit from the trend without actively trading themselves.

    TeamViewer: Success must be preserved

    While wallstreet:online's stock has gained more than 180% within a year, TeamViewer's return is only 31%. This low return is somewhat surprising since TeamViewer was one of the most hyped stocks in 2020 during the first lockdown. But since the summer of 2020, the share price has been moving sideways with a downward trend. Although TeamViewer was able to increase sales and the number of users last year significantly, the Company also invested in the future. TeamViewer opened sales offices around the globe and entered new markets. New competition is also waiting there.

    To defend the market share it gained in 2020, TeamViewer will have to step up its game both technologically and in terms of sales. The market also believes that this situation could become challenging and is cautious about TeamViewer's stock. The Company undoubtedly has good products, but the "home office pie" currently appears to be distributed. Some trends are more promising—for example, the business model of wallstreet:online.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Nico Popp

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author



    Related comments:

    Commented by Carsten Mainitz on October 14th, 2026 | 05:30 CEST

    Tungsten, Weapons and Growth: Almonty, Rheinmetall and Deutz Under Review. Is This an Opportunity in a Megatrend?

    • Tungsten
    • Raw materials
    • Critical raw materials
    • Geopolitics
    • Defence industry
    • Armaments
    • Military
    • Supply chains
    • Investments

    The stock market is not linear. Greed and fear, excessive optimism or excessive scepticism—all of these drive markets. Only the future will tell what is cheap or expensive today. The stocks mentioned above are at precisely this point. Secure supply chains, access to raw materials and defence readiness are high on the agenda of Western governments. These long-term trends play strongly into the hands of defence companies and raw material producers. Almonty, in particular, as a producer of the critical raw material tungsten, holds a leading position in the sector. Where do the greatest opportunities lie for investors now?

    Read

    Commented by Carsten Mainitz on October 14th, 2026 | 05:25 CEST

    Who Profits When Patents Expire? The Billion-Euro Race Between Formycon, Fresenius and Pfizer

    • Biosimilar
    • FDA
    • Milestone
    • Cancer therapy
    • Pharma
    • Patents
    • Investments

    When patent protection for high-revenue biopharmaceuticals expires, a billion-euro market for follow-on products emerges. Michael Sen, head of the German healthcare group Fresenius SE, cites an impressive figure. By 2035, this could generate around EUR 180 billion in revenue. In particular, biosimilars, biotechnologically produced follow-on medicines that are highly similar in composition to the original medicine and equivalent in quality, efficacy and safety, are forecast to grow significantly. Moreover, biosimilars can strengthen competition and reduce treatment costs. Formycon stands out as a pure play. The company recently reached a crucial milestone. The US Food and Drug Administration (FDA) accepted the marketing authorisation application, the first publicly known application of its kind, for FYB206, a biosimilar candidate to the cancer medicine Keytruda, for review. Keytruda generates around USD 32 billion in annual revenue, making it the world's highest-revenue medicine. Fresenius is strengthening its positioning in the biosimilar sector through an acquisition. Pfizer needs new growth drivers. Who is best positioned for the year-end rally?

    Read

    Commented by Matthias Schomber on October 12th, 2026 | 05:24 CEST

    Every Crisis Creates an Opportunity: Nordex Stumbles, Jungheinrich Struggles, and RE Royalties Looks to Have Found a Bottom

    • Investments
    • Trading Opportunity
    • Technical Analysis
    • Rebound

    When market participants suddenly lose their nerve, and industrial heavyweights like Jungheinrich plunge to new multi-year lows despite bulging order books, a key question for private investors, among others, is whether this is a dangerous crisis with further downside ahead or an attractive entry opportunity. Nordex, too, has recently struggled to build on its successes from earlier this year. The share is trapped in a consolidation phase and has now returned to its level from late February, when it broke out upwards on high volume and with a long green weekly candlestick. Is this an attractive entry point for investors desperately seeking stable, high-yield alternatives in the future-oriented renewable energy market? Find out why scepticism could prevail regarding well-known German names and why a pioneer in royalty financing could be on the verge of the next major share price surge following a technical “textbook pattern”.

    Read